J&J to pay $40.5 million to settle New Hampshire opioid lawsuit
Reuters
Published Sep 01, 2022 08:56AM ET
Updated Sep 01, 2022 01:06PM ET
By Jonathan Stempel
(Reuters) -Johnson & Johnson has agreed to pay $40.5 million to settle New Hampshire's claims over the company's role in the U.S. opioid epidemic, averting a trial that had been scheduled to begin next week.
Thursday's settlement resolves a lawsuit brought in 2018 against Johnson & Johnson (NYSE:JNJ) and its Janssen Pharmaceuticals unit.
New Hampshire accused them of aggressively marketing opioids to doctors and patients, misrepresenting their addictive properties when used to treat chronic pain, and targeting vulnerable groups like the elderly.
"This resolution provides a positive step forward in ensuring these devastating business practices are not repeated," Governor Chris Sununu said in a statement.
New Hampshire will apply $31.5 million toward opioid abatement, after paying legal fees, and Johnson & Johnson will be banned from selling or promoting opioids there.
A trial had been scheduled for Sept. 7 in Merrimack County Superior Court.
In a statement, J&J did not admit wrongdoing, and called its marketing and promotion of prescription opioids "appropriate and responsible."
The New Brunswick (NYSE:BC), New Jersey-based drugmaker also said it will defend against other pending opioid litigation.
New Hampshire was one of a few states that did not join Johnson & Johnson's portion of a $26 billion nationwide opioid settlement in February with the company and the three largest U.S. drug distributors, hoping to recover more by suing on its own.
J&J expects to be reimbursed $1.5 million from that settlement because New Hampshire did not participate.
The company said it still faces a lawsuit by Washington state over opioids, and that a trial scheduled for this month had been postponed indefinitely.
More than 500,000 people have died from opioid overdoses nationwide in the past two decades, including a record 75,673 in the year ending April 2021, U.S. government data show.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.